Christine (Chris) Fox joined Novartis Gene Therapies as President in December 2021. She leads the organization in its mission to bring gene therapy to patients and families devastated by rare and life-threatening neurological genetic diseases, starting with the company’s proprietary gene therapy for spinal muscular atrophy.
Prior to this role, Chris was vice president and general manager for the Bone, Cardiometabolic and Nephrology business for Amgen. She also served as the general manager of the company’s United Kingdom and Ireland affiliate. Earlier in her career, she also held leadership positions at Merck, Takeda and several startups.
Chris brings more than 25 years of healthcare industry experience with leadership roles in sales, marketing, and commercial operations, responsible for teams ranging from 2500+ associates to small, nimble consulting teams. She has a deep understanding of issues affecting the pharmaceutical and biotech sectors, as well as expertise across a range of therapy areas including oncology, cardiovascular disease, inflammatory disorders and diabetes.
Chris earned a bachelor’s degree in business marketing from the University of Wisconsin in Whitewater. She and her family currently live in California and will be relocating to the Chicago area in the near future.